CRO/Sponsor

Companies share their experience in future-proofing clinical data technology.

How today’s SSO reduces site burden and spearheads clinical system interoperability.

Strategies for ensuring that innovation with PROs remains parallel with advancements in disease detection and progression.

With close collaboration between sponsors, CROs, and regulators, this emerging technology has the potential to greatly improve the lives of patients.

Survey from the Site Council gathered insights from its members on the quality of site coordinator work.

Addressing data integrity and compliance concerns.

This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, and eCOA.

Examining those technology-supported areas that sponsors, CROs, and sites consider the most valuable.

Insights identify opportunities to optimize sponsor, CRO, and site collaborations.

Clinical trial liaisons rather serve as experts in their therapeutic areas and as clinical trial specialists to provide a suite of strategic advantages to benefit a study.

A focus on data and process excellence advances product development.

How a deeper review of site budget and payment processes and technology is driving meaningful change in the industry.

Strategies for sponsors to utilize technology in reaching diverse patient populations.

Balancing these tools with operational efficiencies can aid CROs in meeting the evolving needs of sponsors.

Use cases spotlight the growing potential of generative AI in the CRO space.

A well-designed approach can benefit clinical trials from protocol design to site support.

Palmese, executive director, site relationships and DCT solutions, discusses the practice of incorporating decentralized elements in a study rather than planning a decentralized trial from the start.

Sponsors and CROs that work with these sites can better reach marginalized communities.

In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, touches on how therapeutic area can affect which labs a sponsor decides to work with.

Results from survey of 100 site personnel suggest a disconnect is present between these stakeholders.

In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, highlights best practices for data standardization and consistency.

In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, discusses the different types of labs in clinical research and what they offer.

In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses the importance of communication between CROs, sponsors, and sites.

It takes a village to raise a trial, but most stakeholders are siloed on isolated islands.

In a fireside chat with ACT editor Andy Studna, Bowdish, from a clinical research cancer center, shares her experience with these relationships and how to streamline clinical operations.

Use case explores the arrangement’s effectiveness in the biometrics setting.

A data-fueled framework for sponsors and CROs in navigating this shifting terrain.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, touches on challenges that may be created by the guidance such as meeting multiple regulatory requirements.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, discusses how sponsors will need to plan ahead even further for their oncology trials.

CRO-sponsor relationships are key as industry moves towards new age of outsourcing.